AI-driven drug repurposing presents opportunities through cost-effective drug development, personalized medicine, and ...

Drug repurposing is emerging as a strategic approach for treating rare and orphan diseases that have limited treatment options. By repurposing existing drugs, companies can potentially shorten ...

As of January 27, the global tally of SARS-CoV-2 infections has surpassed 100 million, with fatalities reaching 2 million. Remarkably, approximately 30 million confirmed cases remain untreated with ...

A research team reports a promising new strategy: combining two already-approved drugs—silybin, a natural liver-protective ...

Drug repurposing and discovery represent a transformative approach in modern pharmacology, seeking to identify new therapeutic uses for existing, approved compounds while also uncovering novel drug ...

Move over, Hugh Laurie: there’s a new Dr. House in town. Harvard Medical School associate professor Marinka Zitnik and her lab announced the development of TxGNN, an artificial intelligence model ...

Using machine learning and a large volume of data on genes and existing drugs, researchers identified a combination of ...

Neratinib, an oral drug commonly used in the treatment of breast cancer, has shown potential in reducing vascular ...

We're all familiar with the dilemma: It takes an average of 9.5 to 15 years to develop a new drug at a cost as high as $2.6 billion, with only a fraction of the drugs making it to market. With AI and ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...

A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together ...